Skip to main content

Table 1 Selected clinical efficacy on selected third generation EGFR TKIs in clinical development

From: Third generation EGFR TKIs: current data and future directions

Third Generation EGFR TKI

Status of development

Trial

Dose

n

ORR

PFS (mth)

(95% CI)

Adverse events

(selected all grade)

Osimertinib

(AZD9291)

Approved for T790 M mutation post EGFR TKI

AURA 3

NCT01802632

80 mg daily

279

71%

(65–76%)

10.1 (8.3–12.3)

Diarrhea (41%); rash (34%), paronychia (22%); pneumonitis (4%)

Olmutinib

Developing in Korea

NCT01588145

800 mg daily

76

56%

7.0

(5.5–8.3)

Diarrhea (55%), rash (39%), nauseas (38%).

Nazartinib (EGF816)

Phase I/II

NCT02108964

75-350 mg QD

132

44%

9.2

(9.0-NE)

Diarrhea (40%), maculopapular rash (39%), pruritus (32%), stomatitis (23%), and fatigue (21%).

Avitinib (AC0010)

Phase I/II

(phase II AEGIS-1 trial had started)

NCT02330367

50-350 mg BID

150-300 mg cohort

136

95

44% a

51%

NA

Diarrhea (38%) and rash (24%)

  1. EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, ORR objective response rate, PFS progression free survival, n number of participant, NE not evaluable, NA not available
  2. a including unconfirmed responses